ECTE Our New Pick

Our newest portfolio company Echo Therapeutics, Inc. (OTCBB: ECTE) holds the potential to revolutionize the >$11 billion worldwide diabetic monitoring industry by being first to market with a non-invasive (needle-free) glucose monitoring system that can make life a lot more comfortable for the world’s nearly 200 million diabetics and . . .

Echo Boasts a Diverse Product Portfolio with Massive Market Potential Clinical testing of ECTE’s “Symphony” system in both hospital and ambulatory environments has been a smashing success. Moreover, pilots have verified that the company has developed a new, cost-effective bio-sensor that is more accurate and less-intrusive than those currently in use. ECTE is now in the process of seeking final FDA approval for its groundbreaking system while simultaneously developing the capabilities necessary to begin mass producing the “Symphony”.

ECTE Boasts a Diverse Product Portfolio with Massive Market Potential

While the “Symphony” system is the first and most advanced product in ECTE’s pipeline, it is certainly not the only one. The company boasts a diverse portfolio of medical devices and specialty pharmaceuticals in various stages of development.

ECTE’s proprietary AzoneTS™ transdermal drug reformulation technology is currently being leveraged to design enhanced versions of commercially successful, FDA-approved products. This is an ingenious strategy that will allow the company to enter established markets that already generate billions of dollars annually with new and improved products that capitalize on the shortcomings of available offerings by being are safer, more efficacious, and more comfortable for patients.

One such product in ECTE’s pipeline is Durhaliev, topical reformulation of triamcinolone acetonide for the treatment of corticosteroid-responsive dermatoses. The corticosteroid market is expected to be worth $3.7B by 2013 and represents another major market opportunity for ECTE.

Recent Trading Activity

The recent pullback in share price from a high print of $1.50 on 11/24 to $1.30 on 12/09 could provide an attractive entry point for risk-averse investors. PPS is currently $.70 below the 52-week high of $2.00 and could rebound to or above that level if news pertaining to recent operational developments surfaces.

Going forward, we’ll be delving deeper into the fundamentals here and look forward to providing a more detailed analysis in the coming days and weeks. For now, however, we suggesting rolling up your sleeves and doing some digging of your own on ECTE.

In our opinion Echo Therapeutics, Inc. (OTCBB: ECTE) represents a very timely and compelling research opportunity and should be on your radar today.